|
[1] Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nature Reviews Drug Discovery, 2009, 8(3): 235-253.
[2] Hajihosseini M K, Heath J K. Expression patterns of fibroblast growth factors-18 and-20 in mouse embryos is suggestive of novel roles in calvarial and limb development. Mechanisms of Development, 2002, 113(1): 79-83.
[3] Jeffers M, McDonald W F, Chillakuru R A, et al. A novel human fibroblast growth factor treats experimental intestinal inflammation. Gastroenterology, 2002, 123(4): 1151-1162.
[4] Maclachlan T, Narayanan B, Gerlach V L, et al. Human fibroblast growth factor 20 (FGF-20; CG53135-05): a novel cytoprotectant with radioprotective potential. International Journal of Radiation Biology, 2005, 81(8): 567-579.
[5] Ohmachi S, Watanabe Y, Mikami T, et al. FGF-20, a novel neurotrophic factor, preferentially expressed in the substantia nigra pars compacta of rat brain. Biochemical and Biophysical Research Communications, 2000, 277(2): 355-360.
[6] Ohmachi S, Mikami T, Konishi M, et al. Preferential neurotrophic activity of fibroblast growth factor-20 for dopaminergic neurons through fibroblast growth factor receptor-1c. Journal of Neuroscience Research, 2003, 72(4): 436-443.
[7] Jeffers M, Shimkets R, Prayaga S, et al. Identification of a novel human fibroblast growth factor and characterization of its role in oncogenesis. Cancer Research, 2001, 61(7): 3131-3138.
[8] Kirikoshi H, Sagara N, Saitoh T, et al. Molecular cloning and characterization of human FGF-20 on chromosome 8p21. 3-p22. Biochemical and Biophysical Research Communications, 2000, 274(2): 337-343.
[9] Plotnikov A N, Eliseenkova A V, Ibrahimi O A, et al. Crystal structure of fibroblast growth factor 9 reveals regions implicated in dimerization and autoinhibition. Journal of Biological Chemistry, 2001, 276(6): 4322-4329.
[10] Kalinina J, Byron S A, Makarenkova H P, et al. Homodimerization controls the fibroblast growth factor 9 subfamily's receptor binding and heparan sulfate-dependent diffusion in the extracellular matrix. Molecular and Cellular Biology, 2009, 29(17): 4663-4678.
[11] Fan H, Vitharana S N, Chen T, et al. Effects of pH and polyanions on the thermal stability of fibroblast growth factor 20. Molecular Pharmaceutics, 2007, 4(2): 232-240.
[12] 时小燕, 郭靓. 成纤维细胞生长因子家族: 生物学特性, 病理生理学作用及相关治疗方法. 国际药学研究杂志, 2009, 36(5): 376-379. Shi X Y, Guo L. Fibroblast growth factor family: biological characteristics, pathophysiological role and related treatment methods. Journal of International Pharmaceutical Research, 2009, 36 (5): 376-379.
[13] Thisse B, Thisse C. Functions and regulations of fibroblast growth factor signaling during embryonic development. Developmental Biology, 2005, 287(2): 390-402.
[14] de Mena L, Cardo L F, Coto E, et al. FGF20 rs12720208 SNP and microRNA-433 variation: no association with Parkinson's disease in Spanish patients. Neuroscience Letters, 2010, 479(1): 22-25.
[15] Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nature Reviews Drug Discovery, 2006, 5(12): 997-1014.
[16] Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell, 2000, 103(2): 311-320.
[17] Huang H, Ushijima T, Nagao M, et al. β-Catenin mutations in liver tumors induced by 2-amino-3, 4-dimethylimidazo quinoline in CDF 1 mice. Cancer Letters, 2003, 198(1): 29-35.
[18] Cui J, Zhou X, Liu Y, et al. Alterations of beta-catenin and Tcf-4 instead of GSK-3beta contribute to activation of Wnt pathway in hepatocellular carcinoma. Chinese Medical Journal, 2003, 116(12): 1885-1892.
[19] Park J Y, Park W S, Nam S W, et al. Mutations of β-catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis. Liver International, 2005, 25(1): 70-76.
[20] Chung G G, Zerkowski M P, Ocal I T, et al. β-Catenin and p53 analyses of a breast carcinoma tissue microarray. Cancer, 2004, 100(10): 2084-2092.
[21] Rowlands T M, Pechenkina I V, Hatsell S, et al. b-Catenin and Cyclin D1: Connecting development to breast cancer. Cell Cycle, 2004, 3(2): 143-146.
[22] Chamorro M N, Schwartz D R, Vonica A, et al. FGF-20 and DKK1 are transcriptional targets of β-catenin and FGF-20 is implicated in cancer and development. The EMBO Journal, 2005, 24(1): 73-84.
[23] 刘萍, 李云峰, 张捷, 等. FGF-20 在结直肠癌中的表达及临床意义. 实用癌症杂志, 2009, 24(4): 358-359. Liu P, Li Y F, Zhang J,et al. The expression of FGF-20 and its clinical significance in the tissues from colorectal cancer. The Practical Journal of Cancer, 2009, 24 (4): 358-359.
[24] Takagi Y, Takahashi J, Saiki H, et al. Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. Journal of Clinical Investigation, 2005, 115(1): 102-109.
[25] van der Walt J M, Noureddine M A, Kittappa R, et al. Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease. The American Journal of Human Genetics, 2004, 74(6): 1121-1127.
[26] Fuchs E. Scratching the surface of skin development. Nature, 2007, 445(7130): 834-842.
[27] Mikkola M L, Millar S E. The mammary bud as a skin appendage: unique and shared aspects of development. Journal of Mammary Gland Biology and Neoplasia, 2006,11(3-4): 187-203.
[28] Schmidt-Ullrich R, Paus R. Molecular principles of hair follicle induction and morphogenesis. Bioessays, 2005, 27(3): 247-261.
[29] Lim X, Nusse R. Wnt signaling in skin development, homeostasis, and disease. Cold Spring Harbor Perspectives in Biology, 2013,5(2):a008029.
[30] Mou C, Jackson B, Schneider P, et al. Generation of the primary hair follicle pattern. Proceedings of the National Academy of Sciences, 2006, 103(24): 9075-9080.
[31] Fliniaux I, Mikkola M L, Lefebvre S, et al. Identification of dkk4 as a target of Eda-A1/Edar pathway reveals an unexpected role of ectodysplasin as inhibitor of Wnt signalling in ectodermal placodes. Developmental Biology, 2008, 320(1): 60-71.
[32] Huh S H, Närhi K, Lindfors PH, et al. Fgf20 governs formation of primary and secondary dermal condensations in developing hair follicles. Genes & Development, 2013, 27(4): 450-458.
[33] Wang G, van der Walt J M, Mayhew G, et al. Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of α-synuclein. The American Journal of Human Genetics, 2008, 82(2): 283-289.
[34] Huh S H, Jones J, Warchol M E, et al. Differentiation of the lateral compartment of the cochlea requires a temporally restricted FGF20 signal. PLoS Biology, 2012, 10(1): e1001231.
[35] Miller R H, Fyffe-Maricich S L. Restoring the balance between disease and repair in multiple sclerosis: insights from mouse models. Disease Models & Mechanisms, 2010, 3(9-10): 535-539.
[36] Han D S, Li F, Holt L, et al. Keratinocyte growth factor-2 (FGF-10) promotes healing of experimental small intestinal ulceration in rats. American Journal of Physiology-Gastrointestinal and Liver Physiology, 2000, 279(5): 1011-1022.
[37] Zhao C, Wang X, Wang J, et al. Effect of moxibustion on the expressions of protein KGF-1, KGF-2 and IL-6 in colon of rats with ulcerative colitis. Journal of Acupuncture and Tuina Science, 2012, 10(3): 138-145.
[38] Alvarez E, Fey E G, Valax P, et al. Preclinical characterization of CG53135 (FGF-20) in radiation and concomitant chemotherapy/radiation-induced oral mucositis. Clinical Cancer Research, 2003, 9(9): 3454-3461.
[39] Schuster M W, Shore T B, Harpel J G, et al. Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant. Supportive Care in Cancer, 2008, 16(5): 477-483.
[40] Maclachlan T, Narayanan B, Gerlach V L, et al. Human fibroblast growth factor 20 (FGF-20; CG53135-05): a novel cytoprotectant with radioprotective potential. International Journal of Radiation Biology, 2005, 81(8): 567-579.
[41] Hayashi T, Ray C A, Bermingham-McDonogh O. Fgf20 is required for sensory epithelial specification in the developing cochlea. The Journal of Neuroscience, 2008, 28(23): 5991-5999.
[42] Sleeman I J, Boshoff E L, Duty S. Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Neuropharmacology, 2012, 63(7): 1268-1277.
[43] Shimada H, Yoshimura N, Tsuji A, et al. Differentiation of dopaminergic neurons from human embryonic stem cells: modulation of differentiation by FGF-20. Journal of Bioscience and Bioengineering, 2009, 107(4): 447-454.
[44] Häärä O, Harjunmaa E, Lindfors P H, et al. Ectodysplasin regulates activator-inhibitor balance in murine tooth development through Fgf20 signaling. Development, 2012, 139(17): 3189-3199.
[45] Kaya F, Mannioui A, Chesneau A, et al. Live imaging of targeted cell ablation in Xenopus: a new model to study demyelination and repair. The Journal of Neuroscience, 2012, 32(37): 12885-12895.
[46] Katoh M, Katoh M, Katoh Y. Comparative genomics on FGF20 orthologs. Oncology Reports, 2005, 14(1): 287-290.
|
